Clinical Trials at Duke Comprehensive Cancer Center


Trial Phase Pediatric Brain Tumors
(Sorted by Stage)
00018926 I A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors SBR Selection: * Will any Duke Medicine facility be a performance site? Yes No Does this study
00014101 I A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
00000052 II A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Glimoas (ACNS0221)
00000294 I A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC-021)
00000505 I/II Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children with Newly Diagnosed Central Nervous System (CNS) Tumors
00010800 III Phase III Randomized Trial of IV Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonusataxia Syndrome Treated with CT and Prednisone
00008017 I/II PBTC-014: Phase I/II Trial of R115777 and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas.
00007357 II COG ACNS0122: Phase II Study to Assess the Ability of Neoadjuvant CT +/- Second Look Surgery to Eliminate All Measurable Disease Prior to RT for NGGCT
00004779 I/II PBTC-016: Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma.
00006531 II Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor or Atypical Teratoid Rhabdoid Tumor
00013541 I A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors
00009530 I A Phase I Clinical Trail of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors
00011956 I PBTC-019 A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Childern with Neoplastic Meningitis
Duke Comprehensive Cancer Center Accolades